HER2 is an erbB/HER type 1 tyrosine kinase receptor that is frequently over-expressed in malignant epithelial tumours. Herceptin, a humanised mouse monoclonal antibody to HER2, is proven therapeutically in the management of metastatic breast cancer, significantly prolonging survival when combined with cytotoxic chemotherapeutic agents. Immunohistochemical studies suggest that non-small-cell lung cancer (NSCLC) tumours may over-express HER2. Our aim was to evaluate HER2 gene amplification and semi-quantitative immuno-expression in NSCLC. A total of 344 NSCLC cases were immunostained for HER2 expression in 2 centres using the HercepTest. HER2 (c-erbB-2 or neu) is a member of the erbB/HER type 1 tyrosine kinase receptor family. This family of receptors mediates proliferation and differentiation in normal epithelial cells. Inappropriate over-expression may contribute to tumour growth and invasion. 1 Over-expression of HER2 has been demonstrated in many epithelial tumours, including breast cancer. 2,3 Over-expression of HER2 on the surface of a tumour cell makes this protein a potential target for the anti-HER2 monoclonal antibody (MAb) construct Herceptin. 4 Herceptin, when combined with cytotoxic chemotherapeutic agents, enhances their anti-tumour activity and significantly prolongs survival in metastatic breast carcinoma. 5,6 Potentially, non-small-cell lung cancer (NSCLC) tumours over-expressing HER2 may also be treated with Herceptin.Previous studies of HER2 expression in NSCLC varied in use of antibodies and immunohistochemical technique as well as the definition of positive cases. Studies on paraffin sections vary in data on membranous and cytoplasmic expression. Membranous staining has been demonstrated in 2% to 40% of NSCLC cases 7,8 and associated with a poor prognosis for adenocarcinoma. 8 Other studies have reported cytoplasmic immunostaining in 10% to 60% of NSCLC cases. 9 -13 Although only membranous expression would be expected to be functionally important, several of these studies have shown cytoplasmic HER2 expression, especially in adenocarcinoma, to be associated with a poor prognosis. 9 -11 One study has shown that NSCLC tumours containing higher levels of HER2 protein have a worse outcome. 14 Another study showed HER2 expression in 17/138 (12%) localised lung adenocarcinomas, with only 1 of these immunopositive cases demonstrating gene amplification. 15 This suggests that, unlike breast carcinoma, HER2 gene amplification in NSCLC is uncommon.The HercepTest was designed as a semi-quantitative immunohistochemical assay to determine HER2 protein over-expression in routinely processed breast cancer tissue, to aid the assessment of patients for whom HER2 antibody treatment with Herceptin is being considered. Cases with a HercepTest staining intensity of 2ϩ or 3ϩ may benefit from Herceptin therapy. 4,16,17 Our aim was to evaluate HER2 expression in NSCLC using the HercepTest and to correlate the results with clinicopathological findings and gene amplification. MATERIAL AND METHODSThis was a retrospect...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.